ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 194

LONG-TERM Efficacy of Tocilizumab in A Patient with Amyloidosis and Interstitial Pneumonia Secondary to Multicentric Castleman’s Disease (MCD)

Michihito Katayama1, Soichiro Tsuji1, Satoshi Teshigawara1, Eriko Kudo-Tanaka1, Maiko Yoshimura1, Akane Watanabe1, Akiko Yura2, Yoshinori Harada3, Yoshinori Katada3, Jun Hashimoto1, Masato Matsushita4, Yukihiko Saeki5 and Shiro Ohshima5, 1Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, 2Dept of Allergology, Allergology,Osaka-Minami Medical Center, Kawachinagano City, Japan, 3Dept of Allergology, Kawachinagano City, Japan, 4Rheumatology, Osaka Minami Medical Center, Osaka, Japan, 5Dept of Clinical Research, Osaka-Minami Medical Center, Kawachinagano City, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Amyloidosis, Castleman's disease, lung and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: Castleman’s disease is a benign lymphoproliferative disorder characterized histologically by follicular hyperplasia and capillary proliferation with endothelial hyperplasia. In addition, overproduction of Interleukin-6 (IL-6) was shown in the germinal centers of hyperplastic lymph node of patients with multicentric Castleman’s disease (MCD), and is implicated in the pathogenesis of MCD. We evaluated long-term efficacy of IL-6 blockade therapy in a patient with both amyloidosis and interstitial pneumonia secondary to MCD.

Methods: A 61-year-old male had abnormal shadows on his chest radiography pointed out by medical checkup in June 1999. Based on the results of a lymph node biopsy in April 2004, he was diagnosed with plasma cell-type MCD. Abnormal shadow on chest radiography indicating interstitial pneumonia, marked anemia, hypoalbuminemia, hypergammaglobulinemia and proteinuria were observed, and got worse gradually. In November 2007, the patient was admitted to our hospital. He showed marked lymphadenopathy at multiple sites, general malaise, low grade fever, loose stool, edema, coughing and dispnea on exercise were observed. The administration of Tocilizumab (TCZ) (8 mg/kg, every 2 weeks) was initiated in December 2007. As his disease activity was extremely high, it is necessary to use concomitant administration of low dose prednisolone to maintain the inflammation low. We monitored clinical findings, laboratory findings, functional test, imaging, and quality of life (QOL) evaluated by SF36 in the patient for four years after initiation of the IL-6 blockade therapy. Moreover, we examined the efficacy of TCZ for the treatment of amyloidosis by intestinal biopsies both at the baseline and one year after first administration of TCZ.

Results: At the baseline, abnormal laboratory findings were as follows; severe anemia, hypoalbuminemia, hypergammaglobulinemia, an elevated CRP level, an elevated serum amyloid A protein (SAA) level, an elevated IL-6 level and proteinuria (2.39 g/day). The results of the respiratory function test indicated obstructive dysfunction of the lung, and blood gases on room air showed hypoxia. Chest CT scan revealed interstitial pneumonia with multiple cysts distributed throughout the lung fields and generalized lymph node enlargement. Endoscopic biopsy of the stomach and duodenum revealed heavy deposition of AA amyloid at the baseline indicating amyloidosis secondary to MCD. TCZ reduced the levels of both CRP and SAA, and improved anemia and hypoalbuminemia. Disappearance of urinary protein was achieved within a year. Lymph nodes throughout the body decreased in size. The results of the images and functional test demonstrated improvement in the patient’s interstitial pneumonia. One year after initiation of treatment with TCZ, endoscopic biopsy of former sampling site of the stomach and duodenum revealed disappearance of AA amyloid. The result of SF36 indicated the improvement both in physical and mental QOL. No severe side effect were observed during the treatment period.

Conclusion: This case report indicates the long-term efficacy of TCZ for the treatment of MCD. Moreover, TCZ is effective for the treatment of amyloidosis, interstitial pneumonia secondary to MCD.


Disclosure:

M. Katayama,
None;

S. Tsuji,
None;

S. Teshigawara,
None;

E. Kudo-Tanaka,
None;

M. Yoshimura,
None;

A. Watanabe,
None;

A. Yura,
None;

Y. Harada,
None;

Y. Katada,
None;

J. Hashimoto,
None;

M. Matsushita,
None;

Y. Saeki,
None;

S. Ohshima,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-efficacy-of-tocilizumab-in-a-patient-with-amyloidosis-and-interstitial-pneumonia-secondary-to-multicentric-castlemans-disease-mcd/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology